Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Sep 28.
Published in final edited form as: Tetrahedron Lett. 2016 Aug 19;57(39):4364–4367. doi: 10.1016/j.tetlet.2016.08.053

Synthesis of 8-(1,2,3-triazol-1-yl)-7-deazapurine nucleosides by azide-alkyne click reactions and direct C-H bond functionalization

Sam Kavoosi 1, Ramanjaneyulu Rayala 1, Brenna Walsh 1, Maria Barrios 1, Walter G Gonzalez 1, Jaroslava Miksovska 1, Logesh Mathivathanan 1, Raphael G Raptis 1, Stanislaw F Wnuk 1,*
PMCID: PMC5322862  NIHMSID: NIHMS813736  PMID: 28239199

Abstract

Treatment of toyocamycin or sangivamycin with 1,3-dibromo-5,5-dimethylhydantoin in MeOH (r.t./30 min) gave 8-bromotoyocamycin and 8-bromosangivamycin in good yields. Nucleophilic aromatic substitution of 8-bromotoyocamycin with sodium azide provided novel 8-azidotoyocamycin. Strain promoted click reactions of the latter with cyclooctynes resulted in the formation of the 1,2,3-triazole products. Iodine-mediated direct C8-H bond functionalization of tubercidin with benzotriazoles in the presence of tert-butyl hydroperoxide gave the corresponding 8-benzotriazolyltubercidin derivatives. The 8-(1,2,3-triazol-1-yl)-7-deazapurine derivatives showed moderate quantum yields and a large Stokes shifts of ~ 100 nm.

Keywords: Azido Nucleosides, Click Chemistry, Deazapurine nucleosides, Direct C-H Functionalization, Fluorescence, Triazoles

Graphical Abstract

graphic file with name nihms813736f6.jpg


Synthetic transformations, biological activities and physicochemical properties of 7-deazapurine derivatives (mainly tubercidin, toyocamycin, and sangivamycin antibiotics) have been extensively studied19 and are subject of the excellent reviews.1012 In recent years 7-deazapurine nucleosides have been explored as substrates for 1,4-regioselective copper-catalyzed azide/alkyne cycloaddition (CuAAC), which resulted in developing fluorogenic DNA probes.1316 These studies have mainly concentrated on the application of 7-alkynyl derivatives of 7-deazapurines and 7-deazanucleosides for the preparation of the fluorescent 1,2,3-triazol-4-yl probes.4,1718 Studies with 7-azido-7-deazapurine nucleosides as well as 8-azido- or 8-alkynyl-7-deazapurine nucleosides have received much less attention due to the lack of availability of the convenient synthetic protocols for their synthesis.17,19 This is despite the fact that azidonucleosides2022 including 8-azido as well as 8-alkynyl purine23 nucleosides have been used as convenient substrates for CuAAC and strain-promoted azide-alkyne cycloaddition (SPAAC).2426 This approach is rapidly growing field with various applications, including in vivo imaging, of azido/alkyne-modified nucleoside/nucleotides2627 or DNA/RNA fragment click adducts.2833

Herein, we report two independent methods for the synthesis of novel 8-triazol-1-yl derivatives of 7-deazapurine nucleosides. One protocol involves strain-promoted click chemistry between 8-azido-7-deazapurine nucleosides and cyclooctynes whereas the second approach explores direct C8-H bond functionalization of 7-deazapurine nucleosides and coupling with benzotriazoles.

The synthesis of the 8-azido-7-deazapurines (3a–c) was attempted from 8-halo-7-deaza substrates. Thus, bromination of 2',3',5'-tri-O-acetyltubercidin 1a using recently reported protocols for the C-8 bromination of purine nucleosides,34 employing 1,3-dibromo-5,5-dimethylhydantoin (DBH, 0.65 eq.) in CH2Cl2 at 0 °C for 40 min, provided 7-bromo 2a (32%) in addition to 7,8-dibromo 2b (10%, TLC; Scheme 1). Deacetylation of 2a and 2b with methanolic ammonia gave 7-bromotubercidin 2c (80%) and 7,8-dibromotubercidin 2d (57%). Treatment of tubercidin 1b with N-bromosuccinimide (NBS, 2 eq.) in presence of KOAc in DMF yielded 8-bromotubercidin35 2e (34%), whereas attempted bromination of 1b with DBH in DMF gave a complex reaction mixture.

Scheme 1.

Scheme 1

Synthesis of 8-bromo- and 8-azido-7-deazapurine nucleosides.

The 8-bromination of toyocamycin 1c with 0.75 equiv. of DBH in MeOH (30 min.) proceeded efficiently to give after crystallization 2f (85%). Treatment of 1c with NBS (1.1 eq.) in DMF at r.t. for 2.5 h also yielded 2f (45%) after column chromatography. Replacement of DMF with MeOH gave 2f (64%) after crystallization, although reaction took 4 h for completion. The 8-bromotoyocamycin (2f) has been previously prepared either by coupling of the corresponding 8-bromo-7-deazapurine with the ribose precursor36 or by bromination of toyocamycin 1c with Br2/H2O (61%).37 Thus the DBH/MeOH combination is the most efficient for synthesizing 2f in terms of yield, reaction time, and product isolation.

Treatment of sangivamycin 1d with DBH (1.1 eq.) in MeOH (r.t., 30 min) yielded 2g (63%), whereas bromination of 1d with NBS (1.5 eq.) in DMF for 1.5 h gave 2g in 40% yield in addition to unidentified byproducts. The synthesis of 8-bromosangivamycin 2g is usually achieved by the hydrolysis of 8-bromotoyocamycin 2f with a concentrated NH4OH and 50% H2O2 solution.36

Attempts to synthesize 8-azidotubercidin 3a from 8-bromotubercidin 2e [NaN3 (1–5 eq)/DMF/rt-153 °C; NaN3 (3 eq)/TsOH (3 eq)/EtOH/reflux) were unsuccessful. The higher electron density of π-excessive pyrrole ring most probably prevented the nucleophilic substitution reaction. However, treatment of 8-bromotoyocamycin 2f with NaN3 in DMF at room temperature for 16 h produced 8-azidotoyocamycin 3b in 46% isolated yield (70%, based on TLC and 1H NMR of the crude reaction mixture). Although this azidation reaction was light- and heat-sensitive and required the reaction, purification, and characterization to be carried out in the dark, the isolated 8-azido product 3b was stable for days when stored in refrigerator at 4 °C.23,38 The presence of the EWG on the 7-position of the pyrrole ring in toyocamycin, as compared to tubercidin, could be the reason for successful substitution of bromide by azide in 2f. Treatment of 8-bromosangivamycin 2g with NaN3 in DMF (as well as in DMSO or MeOH) at r.t or 70 °C failed to produce the desired 8-azidosangivamycin 3c.

SPAAC reaction of 8-azidotoyocamycin 3b with symmetrically fused cyclopropyl cyclooctyne 4 (OCT) in an aqueous solution of acetonitrile (ACN) at ambient temperature (4 h) gave the 8-(1,2,3-triazol-1-yl) product 5 as mixture of two isomers (60%, Scheme 2). Analogous reaction (4 h) of 3b with a strain modulated dibenzylcyclooctyne 6 (DBCO) produced triazole 7 as mixture of isomers (47%) after RP-HPLC purification. The resulting triazolyl products have "light-up" (inherited) fluorescent properties (Table 1), due to increased conjugation in the 7-deazapurine ring, and can therefore be used for fluorescent imaging in cancer cells, as recently reported with 8-triazolyl purine and 5-triazolyl pyrimidine nucleosides.2627 CuAAC reaction of 8-azido 3b with phenylacetylene in aqueous MeOH (4 days/r.t.) gave 8-(4-phenyl-1H-1,2,3-triazol-1-yl)toyocamycin 9 (65%) after silica column purification.

Scheme 2.

Scheme 2

Click reactions between 8-azidotoyocamycin and cyclooctynes 4, 6 and phenylacetylene 8.

Table 1.

Photophysical data for 8-(1,2,3-triazol-1-yl)-7-deazapurine nucleosides.

5 7 9 10 11a 12a
εmax (M−1 cm−1) 12200 12600 16000 16700 17100 17700
λmax (abs)b (nm) 287 290 295 278 278 276
λmax (exc)b (nm) 295 299 301 321 322 343
λmax (emi)b (nm) 380 434 412 416 419 480
Stokes Shift (nm) 85 135 111 95 97 137
ϕFb (%) 1.4 0.5 0.4 0.2 0.7 0.8
a

As mixture of 5- and 6-isomers.

b

In MeOH

Our attempts to prepare 8-alkynyl-7-dezapurine derivatives, which could serve as substrates for the synthes0is of the underdeveloped 8-(1,2,3-triazol-4-yl) adducts via click reactions with organoazides were unsuccessful. Thus, treatment of 8-bromotubercidin (2e), 8-bromotoyocamycin (2f), 8-bromo-2',3',5'-tri-O-acetyltoyocamycin,39 or 8-iodotoyocamycin [prepared by treatment of the silylated toyocamycin with LDA (5 equiv.) and iodine (I2, 1.5 equiv.) in THF (16%)] with trimethylsilylacetylene (TMSA) in the presence of TEA and (PPh3)2PdCl2/CuI in anhydrous DMF showed mainly unchanged starting material under various reaction conditions. These results are in sharp contrast to 7-halo-7-deazapurines that undergo smooth Sonagashira cross-coupling providing 7-alkynyl analogues, which after further modifications provide derivatives with interesting photophysical and biological properties.4,17

Since syntheses of 8-azidotubercidin 3a for the click reactions were unsuccessful, the possibility to prepare 8-triazolyl adducts of tubercidin 1b, using a direct C8-H activation of the 7-deazapurine ring, was explored next. Direct C-H fuctionalization of purines and purine nucleosides has recently gained much attention.19,4043 The examples include regioselective Pd-catalyzed direct C8-H arylation of the 6-phenyl-7-deazapurines with aryl halides to provide 8-arylated products albeit in low to moderate yields.44 A regioselective direct C-H amination of the 7-deazapurines to give access to the 8-amino-,45 or 7-amino-7-deazapurine analogues has been also reported.46 We found that treatment of tubercidin 1b with benzotriazole (2 equiv.) in the presence of I2 (0.4 equiv.) and tert-butylhydroperoxide (TBHP; 5–6 M/decane, 2 equiv.)47 in anhydrous DMF at 35 °C for 96 h showed ~30% conversion (TLC) to 8-(benzotriazol-1-yl)tubercidin 10 which was isolated in 18% yield after column chromatography and HPLC (Scheme 3). Increasing the amount of iodine from catalytic to stoichiometric (3 equiv.) afforded 10 in 35% yield after 16 h. 1H NMR data showed that the 7.60 ppm doublet for H7 in 1b collapsed to a singlet at 7.04 ppm in 10.

Scheme 3.

Scheme 3

Iodine-mediated oxidative cross-coupling of tubercidin with benzotriazole.

The C8 regioselectivity for the oxidative cross-coupling product 10 was established by a X-ray crystal structure determination (Figure 1).48 It is noteworthy that the 7-deazapurine ring and the benzotriazole ring are twisted to each other with an angle of 67.9° between the planes, which does not favor intermolecular π-π interactions. The glycosyl torsion angle C4–N9–C1′–O4' is 59.8° (syn conformation) and the furanose pseudorotation angle49 is 162.9° (2E conformation). The C3'–C4'–C5'–O5′ torsion angle is 54.1° and is in g+/gg range.

Figure 1.

Figure 1

X-ray crystal structure of 10 showing atom labeling. Solvent molecules and H-atoms are omitted for clarity.

Treatment of 1b with 5-methylbenzotriazole [I2 (0.2 equiv.)/TBHP/DMF/rt/5 days] produced a 3:2 mixture of 5-methyl- and 6-methylbenzotriazol-1-yl adducts 11a/11b (6%). Reaction with stoichiometric amount of iodine (3 equiv.) resulted in the efficient conversion to 11a/11b (48%; ~80% based on TLC after 15 min.), showing generality of the iodine-mediated direct activation of tubercidin ring at C8. Analogous treatment of 1b with 5-chlorobenzotriazole (3 equiv.) produced 5/6-chlorobenzotriazol-1-yl adducts 12a/12b (1:1, 21%; ~60% conversion on TLC). Because 7-deazapurine is structurally similar to indole, the coupling of 1b with benzotriazole might have occurred via initial iodination of the pyrrole ring of 7-deazapurine followed by trapping of the resulting iodonium, or 7-iodo iminium intermediates, with nucleophilic triazole. Subsequent elimination of HI, as proposed for the iodine-catalyzed direct activation of indoles with azoles mediated by TBHP,47 should yield products 10–12. Subjection of the sangivamycin 1c and toyocamycin 1b to direct C8-H functionalization with benzotriazole (r.t. to 80 °C/48 h) gave unchanged substrate or resulted in rather complex reaction mixture. These results reiterate the literature report that the iodine catalyzed C-H activation of indoles with azoles works rather sluggishly with electron deficient indole substrates.47

The photophysical properties of 8-(1,2,3-triazol-1-yl)-7-deazapurine adducts 5, 7, 9 and 10–12 were determined in MeOH. All triazol derivatives have similar absorption and excitation spectra with an absorption maximum between 276 nm and 295 nm and comparable extinction coefficient values (Table 1 and Figure S2). Moderate quantum yields and a large Stokes shifts of ~ 100 nm observed here are analogous to the fluorescence properties of aliphatic and benzylic derivatives of 1-(purin-8-yl)triazoles.23 The emission maximum of triazol 5 (380 nm) is blue shifted compared to other derivatives (412–480 nm), likely due to the absence of an aromatic substituent (Figure 2). Emission spectrum of chloro substituted benzotriazole 12 is red-shifted compared to benzotriazoles 10 and 11, suggesting a resonance conjugation between the aromatic ring and Cl electrons.

Figure 2.

Figure 2

Emission spectra for 8-(1,2,3-triazol-1-yl)-7-deazapurine nucleosides.

Emission properties of the triazole 10 were also investigated in aqueous solutions. Compound 10 is fluorescent at neutral and basic pH (7.0 to 12.0) and becomes non-fluorescent at acidic pH. Interestingly, compounds 10 and 11 seem to be highly sensitive to UV light, as an increase in emission intensity (8.1 and 2.4 fold) upon irradiation with 280 nm light was observed (Figure S3). Triazole 10 has an average lifetime about 3.8 ns with two well-defined components 1 ns (10%) and 4.1 ns (90%).

In summary, bromination of 7-deazapurine nucleosides with DBH/MeOH gave 8-bromotoyocamycin and 8-bromosangivamycin in high yields. Treatment of the 8-bromotoyocamycin with sodium azide yielded 8-azidotoyocamycin. Strain promoted click chemistry of 8-azidotoyocamycin with cyclooctynes provided the corresponding 8-triazol-1-yl products. Iodine-mediated direct C-H arylation of tubercidin with benzotriazoles gave the corresponding 8-(benzotriazol-1-yl)tubercidin products. The 8-(1,2,3-triazol-1-yl)-7-deazapurine derivatives showed moderate quantum yields and a large Stokes shifts of ~ 100 nm.

Supplementary Material

NIHMS813736-supplement.docx (247.9KB, docx)

Highlights.

  • Efficient bromination of 7-deazapurine nucleosides with DBH in MeOH

  • Click reactions of 8-azidotoyocamycin with alkynes gave fluorescent triazoles

  • Direct C8-H bond functionalization of tubercidin with benzotriazoles

Acknowledgments

We would like to express our gratitude to Dr. Morris J. Robins for generous donation of 7-deazapurine substrates, NSF-REU (Grant No: CHE1156886 to FIU) for support to BW (James Madison University), FIU MBRS program (NIH/NIGMS R25 GM061347) for support to WGG, and FIU University Graduate School for Dissertation Year Fellowship to RR.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Supplementary data associated with this article can be found, in online version, at http://dx.doi.10.1016/j.tetlet.

References and notes

  • 1.Bookser BC, Ugarkar BG, Matelich MC, Lemus RH, Allan M, Tsuchiya M, Nakane M, Nagahisa A, Wiesner JB, Erion MD. J. Med. Chem. 2005;48:7808–7820. doi: 10.1021/jm050394a. [DOI] [PubMed] [Google Scholar]
  • 2.Kawate T, Allerson CR, Wolfe JL. Org. Lett. 2005;7:3865–3868. doi: 10.1021/ol051144r. [DOI] [PubMed] [Google Scholar]
  • 3.Seela F, Xu K. Org. Biomol. Chem. 2008;6:3552–3560. doi: 10.1039/b806145a. [DOI] [PubMed] [Google Scholar]
  • 4.Bourderioux A, Naus P, Perlikova P, Pohl R, Pichova I, Votruba I, Dzubak P, Konecny P, Hajduch M, Stray KM, Wang T, Ray AS, Feng JY, Birkus G, Cihlar T, Hocek M. J. Med. Chem. 2011;54:5498–5507. doi: 10.1021/jm2005173. [DOI] [PubMed] [Google Scholar]
  • 5.Naus P, Caletkova O, Konecny P, Dzubak P, Bogdanova K, Kolar M, Vrbkova J, Slavetinska L, Tloust'ova E, Perlikova P, Hajduch M, Hocek M. J. Med. Chem. 2014;57:1097–1110. doi: 10.1021/jm4018948. [DOI] [PubMed] [Google Scholar]
  • 6.Rayala R, Theard P, Ortiz H, Yao S, Young JD, Balzarini J, Robins MJ, Wnuk SF. Chem Med Chem. 2014;9:2186–2192. doi: 10.1002/cmdc.201402047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Snasel J, Naus P, Dostal J, Hnizda A, Fanfrlik J, Brynda J, Bourderioux A, Dusek M, Dvorakova H, Stolarikova J, Zabranska H, Pohl R, Konecny P, Dzubak P, Votruba I, Hajduch M, Rezacova P, Veverka V, Hocek M, Pichova I. J. Med. Chem. 2014;57:8268–8279. doi: 10.1021/jm500497v. [DOI] [PubMed] [Google Scholar]
  • 8.Kielkowski P, Fanfrlik J, Hocek M. Angew. Chem. Int. Ed. Engl. 2014;53:7552–7555. doi: 10.1002/anie.201404742. [DOI] [PubMed] [Google Scholar]
  • 9.Takano S, Tsuzuki T, Murayama T, Sakurai T, Fukuda H, Arisawa M, Shuto S. J. Org. Chem. 2015;80:6619–6627. doi: 10.1021/acs.joc.5b00723. [DOI] [PubMed] [Google Scholar]
  • 10.Seela F, Peng X. Curr. Top. Med. Chem. 2006;6:867–892. doi: 10.2174/156802606777303649. [DOI] [PubMed] [Google Scholar]
  • 11.Seela F, Peng X, Budow S. Curr. Org. Chem. 2007;11:427–462. [Google Scholar]
  • 12.Seela F, Budow S, Peng X. Curr. Org. Chem. 2012;16:161–223. [Google Scholar]
  • 13.Seela F, Ingale SA. J. Org. Chem. 2010;75:284–295. doi: 10.1021/jo902300e. [DOI] [PubMed] [Google Scholar]
  • 14.Seela F, Pujari SS. Bioconjugate Chem. 2010;21:1629–1641. doi: 10.1021/bc100090y. [DOI] [PubMed] [Google Scholar]
  • 15.Ingale SA, Pujari SS, Sirivolu VR, Ding P, Xiong H, Mei H, Seela F. J. Org. Chem. 2012;77:188–199. doi: 10.1021/jo202103q. [DOI] [PubMed] [Google Scholar]
  • 16.Xiong H, Leonard P, Seela F. Bioconjugate Chem. 2012;23:856–870. doi: 10.1021/bc300013k. [DOI] [PubMed] [Google Scholar]
  • 17.Tumkevicius S, Dodonova J. Chem. Heterocycl. Compd. 2012;48:258–279. [Google Scholar]
  • 18.Lawson CP, Dierckx A, Miannay FA, Wellner E, Wilhelmsson LM, Grotli M. Org. Biomol. Chem. 2014;12:5158–5167. doi: 10.1039/c4ob00904e. [DOI] [PubMed] [Google Scholar]
  • 19.Klečka M, Poštová Slavětínská L, Hocek M. Eur. J. Org. Chem. 2015;2015:7943–7961. [Google Scholar]
  • 20.Smyslova P, Popa I, Lycka A, Tejral G, Hlavac J. PloS One. 2015;10:e0144613. doi: 10.1371/journal.pone.0144613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ozols K, Cīrule D, Novosjolova I, Stepanovs D, Liepinsh E, Bizdēna Ē, Turks M. Tetrahedron Lett. 2016;57:1174–1178. [Google Scholar]
  • 22.Cīrule D, Ozols K, Platnieks O, Bizdēna Ē, Māliņa I, Turks M. Tetrahedron. 2016;72:4177–4185. [Google Scholar]
  • 23.Redwan IN, Bliman D, Tokugawa M, Lawson C, Grøtli M. Tetrahedron. 2013;69:8857–8864. [Google Scholar]
  • 24.Dyrager C, Börjesson K, Dinér P, Elf A, Albinsson B, Wilhelmsson LM, Grøtli M. Eur. J. Org. Chem. 2009;2009:1515–1521. [Google Scholar]
  • 25.Novosjolova I, Bizdēna Ē, Turks M. Eur. J. Org. Chem. 2015;2015:3629–3649. [Google Scholar]
  • 26.Zayas J, Annoual MD, Das JK, Felty Q, Gonzalez WG, Miksovska J, Sharifai N, Chiba A, Wnuk SF. Bioconjug. Chem. 2015;26:1519–1532. doi: 10.1021/acs.bioconjchem.5b00300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ito K, Liu H, Komiyama M, Hayashi T, Xu Y. Molecules. 2013;18:12909–12915. doi: 10.3390/molecules181012909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gramlich PME, Wirges CT, Manetto A, Carell T. Angew. Chem. Int. Ed. 2008;47:8350–8358. doi: 10.1002/anie.200802077. [DOI] [PubMed] [Google Scholar]
  • 29.Marks IS, Kang JS, Jones BT, Landmark KJ, Cleland AJ, Taton TA. Bioconjug. Chem. 2011;22:1259–1263. doi: 10.1021/bc1003668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Guan L, van der Heijden GW, Bortvin A, Greenberg MM. ChemBioChem. 2011;12:2184–2190. doi: 10.1002/cbic.201100353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Shelbourne M, Chen X, Brown T, El-Sagheer AH. Chem. Commun. 2011;47:6257–6259. doi: 10.1039/c1cc10743g. [DOI] [PubMed] [Google Scholar]
  • 32.Heuer-Jungemann A, Kirkwood R, El-Sagheer AH, Brown T, Kanaras AG. Nanoscale. 2013;5:7209–7212. doi: 10.1039/c3nr02362a. [DOI] [PubMed] [Google Scholar]
  • 33.Neef AB, Luedtke NW. Chem Bio Chem. 2014;15:789–793. doi: 10.1002/cbic.201400037. [DOI] [PubMed] [Google Scholar]
  • 34.Rayala R, Wnuk SF. Tetrahedron Lett. 2012;53:3333–3336. doi: 10.1016/j.tetlet.2012.04.081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Bergstrom DE, Brattesani AJ. Nucleic Acids Res. 1980;8:6213–6219. doi: 10.1093/nar/8.24.6213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Tolman RL, Robins RK, Townsend LB. J. Amer. Chem. Soc. 1969;91:2102–2108. doi: 10.1021/ja01036a040. [DOI] [PubMed] [Google Scholar]
  • 37.Tolman RL, Robins RK, Townsend LB. J. Heterocycl. Chem. 1971;8:703–706. [Google Scholar]
  • 38.The 8-azidopurines were reported to be light sensitive and were directly used in coupling with alkynes without prior purification (Ref. 23).
  • 39.Kim Y-J, Kwon SH, Bae IH, Kim BM. Tetrahedron Lett. 2013;54:5484–5488. [Google Scholar]
  • 40.De Ornellas S, Storr TE, Williams TJ, Baumann CG, Fairlamb IJS. Curr. Org. Synth. 2011;8:79–101. [Google Scholar]
  • 41.De Ornellas S, Williams TJ, Baumann CG, Fairlamb IJS. RSC Catal. Ser. 2013;11:409–447. [Google Scholar]
  • 42.Gayakhe V, Sanghvi YS, Fairlamb IJS, Kapdi AR. Chem. Commun. 2015;51:11944–11960. doi: 10.1039/c5cc03416g. [DOI] [PubMed] [Google Scholar]
  • 43.Liang Y, Wnuk S. Molecules. 2015;20:4874–4901. doi: 10.3390/molecules20034874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Klecka M, Pohl R, Klepetarova B, Hocek M. Org. Biomol. Chem. 2009;7:866–868. doi: 10.1039/b900218a. [DOI] [PubMed] [Google Scholar]
  • 45.Sabat N, Klecka M, Slavetinska L, Klepetarova B, Hocek M. RSC Advances. 2014;4:62140–62143. [Google Scholar]
  • 46.Sokolovs I, Lubriks D, Suna E. J. Am. Chem. Soc. 2014;136:6920–6928. doi: 10.1021/ja502174d. [DOI] [PubMed] [Google Scholar]
  • 47.Beukeaw D, Udomsasporn K, Yotphan S. J. Org. Chem. 2015;80:3447–3454. doi: 10.1021/jo502933e. [DOI] [PubMed] [Google Scholar]
  • 48.Crystallographic data for 8-(benzotriazol-1-yl)tubercidin 10 have been deposited with the Cambridge Crystallographic Data Center as a supplementary publication No. CCDC-1487054.
  • 49.Altona C, Sundaralingam M. J. Am. Chem. Soc. 1972;94:8205–8212. doi: 10.1021/ja00778a043. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

NIHMS813736-supplement.docx (247.9KB, docx)

RESOURCES